ArticleTheranostics2025
PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.
Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- SNAI2/SLUG: a key regulator of endothelial-to-mesenchymal transition and vascular remodeling in cardiovascular diseases.Journal of cardiothoracic surgery · 2026Review
- Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- The Trojan Horse system composed of platelet membrane and extracellular vesicles inhibits atherosclerotic plaque progression.iScience · 2026Article
- KAP1 SUMOylates and stabilizes SR-A to facilitate glycated LDL transcytosis and accelerate atherosclerosis.Cellular & molecular biology letters · 2026Article
- ZIKV NS3 disrupts Nrf2-mediated antioxidant defense and drives vascular smooth muscle cell damage and vascular dysfunction.Zoological research · 2026Article
- Integrative single-cell analysis reveals endothelial diversity in the vasa vasorum of human atherosclerosis.Communications biology · 2026Article
- Valvular Leaflets Are Not Innocent Bystanders: Divergent Fibrotic Remodeling Accompanies Functional Mitral and Tricuspid Regurgitation.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Oscillatory shear stress-driven endothelial-to-mesenchymal transition: a critical mechanical signal transduction mechanism in atherosclerosis progression.Cell death discovery · 2026Review
- Endothelial to mesenchymal transition in cardiovascular diseases: molecular insights and clinical perspectives.European heart journal · 2026Review
- Neferine inhibits vascular smooth muscle cell proliferation and migration in atherosclerosis by targeting CYS130 and PHE252 in PTEN.Frontiers in pharmacology · 2026Article
- Emerging insights into inflammation-driven atherosclerosis: immune cell mechanisms.Frontiers in cardiovascular medicine · 2026Review
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- Integrated Single-Cell and Bulk Transcriptomic Analysis Reveals an Endothelial Gene Signature Shaping EndMT and Prognosis in Hepatocellular Carcinoma.Human mutation · 2026Article
- NDRG1 as a sensor and mediator of endothelial stress: from homeostasis to inflammation and cardiovascular disease.Cellular and molecular life sciences : CMLS · 2025Review
- Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36.bioRxiv : the preprint server for biology · 2025Article
- The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?Current atherosclerosis reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.